Neoadjuvant chemotherapy (NACT) selection for advanced stage ovarian cancer (AOC) at a comprehensive cancer center.

被引：0
|
作者：
Mueller, Jennifer J.
Alvi, Farah Abbas
El Haraki, Amr S.
Eriksson, Ane Gerda
Zhou, Qin
Iasonos, Alexia
O'Cearbhaill, Roisin Eilish
Chi, Dennis
Abu-Rustum, Nadeem
Zivanovic, Oliver
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Weill Cornell Med Coll, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16579
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16579
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer
    Kessous, Roy
    Laskov, Ido
    Abitbol, Jeremie
    Bitharas, Joanna
    Yasmeen, Amber
    Salvador, Shannon
    Lau, Susie
    Gotlieb, Walter H.
    GYNECOLOGIC ONCOLOGY, 2017, 144 (03) : 474 - 479
  • [42] The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer
    Pectasides, D
    Farmakis, D
    Koumarianou, A
    ONCOLOGY, 2005, 68 (01) : 64 - 70
  • [43] The potential role of neoadjuvant chemotherapy in advanced ovarian cancer
    Baekelandt, M
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 : 163 - 168
  • [44] Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
    du Bois, Andreas
    Baert, Thais
    Vergote, Ignace
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27) : 2398 - +
  • [45] Use of neoadjuvant chemotherapy in advanced ovarian cancer.
    Meyer, Larissa
    Cronin, Angel
    Sun, Charlotte C.
    Bookman, Michael A.
    Burger, Robert Allen
    Cristea, Mihaela C.
    Griggs, Jennifer J.
    Levenback, Charles F.
    Mantia-Smaldone, Gina
    Matulonis, Ursula
    Niland, Joyce C.
    O'Malley, David M.
    Wright, Alexi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Neoadjuvant chemotherapy in the Medicare cohort with advanced ovarian cancer
    Thrall, Melissa M.
    Gray, Heidi J.
    Symons, Rebecca Gaston
    Weiss, Noel S.
    Flum, David R.
    Goff, Barbara A.
    GYNECOLOGIC ONCOLOGY, 2011, 123 (03) : 461 - 466
  • [47] Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?
    Narod, Steven
    Sopik, Victoria
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 238 - 240
  • [48] Racial effect of early stage colorectal cancer outcomes in a comprehensive cancer center.
    Fangman, Benjamin D.
    Beg, Muhammad Shaalan
    Sanjeevaiah, Aravind
    Araghizadeh, Farshid
    Scielzo, Shannon
    Kazmi, Syed Mohammad Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [49] Characteristics and outcomes of cancer patients ≥80 years treated with chemotherapy at a comprehensive cancer center.
    Jiang, P.
    Choi, M.
    Smith, D.
    Heilbrun, L.
    Gadgeel, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 480S - 480S
  • [50] Checkpoint blockade combined with neoadjuvant chemotherapy (NACT) in advanced-stage epithelial ovarian cancer (EOC): preliminary results from a phase II clinical trial
    Huang, Marilyn
    Pinto, Andre
    Castillo, R. Patricia
    Schlumbrecht, Matthew
    Pearson, Joseph
    Sinno, Abdulrahman
    George, Sophia
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S62 - S62
12345